Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2025-12-25 @ 12:43 AM
NCT ID:
NCT00252967
Eligibility Criteria:
Inclusion Criteria:
* \> or = 18 years of age
* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
* Able to swallow pill form of drug
Exclusion Criteria:
* \< 18 years of age
* enrollment in another ongoing trial
* paroxysmal atrial fibrillation
* hemodynamic instability
* atrial fibrillation ablation within 6 months of enrollment
* a contraindication for anticoagulation
* severe valvular heart disease
* presence of single lead implantable cardioverter defibrillator
* unstable angina
* New York Heart Association (NYHA) Class IV heart failure
* hyperthyroidism
* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications
* an illness that would limit life expectancy to less than 1 year
* use of statins within the previous 30 days
* significant coronary artery disease or lipid abnormalities necessitating statin therapy
* implanted devices for active management of arrhythmias by pacing or defibrillation
* lack of access to a telephone
* illicit drug use
* alcohol abuse
* hypersensitivity to atorvastatin by history
* pregnancy
* sexually active female subjects not on contraception or surgically sterilized
* nursing mothers
* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)
* severe renal disease (creatinine \> 200 mmol/L)
* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN
* concurrent treatment with cyclosporine, fibrates, or high-dose niacin
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00252967
Study Brief:
Protocol Section:
NCT00252967